Physician profile
Marco Shaker
NPI 1508361577
$13,669.71
in general payments reported to CMS, 2019-2025
28 companies · $3,697 in 2025
The $3,697 reported for 2025 was more than what 79% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.22 · 2022: $2,772 · 2023: $2,685 · 2024: $4,504 · 2025: $3,697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,059 · Grant: $3,000 · Travel and Lodging: $2,776 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,058.78 |
| Grant | $3,000.00 |
| Travel and Lodging | $2,776.29 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $5,870.92 | 2022-2025 | Turbohawk, Abre, Symplicity G3 |
| Biotronik INC. | $2,022.97 | 2022 | |
| Penumbra, INC. | $1,293.62 | 2024-2025 | Indigo System |
| Abiomed | $1,153.99 | 2023-2025 | Impella |
| Teleflex LLC | $400.21 | 2024-2025 | Turnpike |
| Inari Medical, INC. | $349.41 | 2022-2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Abbott Laboratories | $301.35 | 2023-2025 | Diamondback Coronary, Cardiomems, Perclose Proglide |
| Novartis Pharmaceuticals Corporation | $261.70 | 2024-2025 | |
| Becton, Dickinson and Company | $237.71 | 2024-2025 | Hemosphere |
| Boston Scientific Corporation | $213.93 | 2022-2025 | Stingray, Eluvia |
| Endologix LLC | $197.03 | 2025 | Endocross Device, Torus Stent Graft System |
| Shockwave Medical, INC | $176.89 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave E8 Peripher |
| Novo Nordisk INC | $158.82 | 2025 | Wegovy |
| Asahi Intecc USA, INC. | $154.96 | 2025 | Asahi Coronary Wires |
| Astrazeneca Pharmaceuticals Lp | $148.67 | 2022-2024 | Farxiga |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $145.59 | 2025 | Puraply Wound Matrix |
| Cardiovascular Systems INC. | $144.49 | 2022 | |
| Janssen Pharmaceuticals, INC | $74.37 | 2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $61.86 | 2024-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $60.39 | 2023-2024 | Verquvo |
| W. L. Gore & Associates, INC. | $50.00 | 2024 | Gore-Tex Vascular Graft |
| Livanova USA, INC. | $37.93 | 2023 | Tandemheart |
| Atricure, INC. | $35.51 | 2024 | |
| Cardiva Medical, INC. | $33.50 | 2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Chiesi USA, INC. | $28.92 | 2024 | Cleviprex, Kengreal |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.35 | 2024 | Jardiance |
| Edwards Lifesciences Corporation | $17.40 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Genentech USA, INC. | $12.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marco Shaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.